Fig. 8

Inhibition of RBX1 sensitizes 17p^loss CRPC to the treatment of α-amanitin-based ADC. a Schematic illustration of orthotopic injection of 17p^loss DU145 cells (1 × 10⁶ cells) followed by twice i.p. injection of ADC and Dox food treatment. b, c Representative bioluminescent tumor images and individual tumor growth curves of xenograft tumors derived from orthotopically implanted 17p^loss DU145 cells without (b) or with (c) Dox treatment. Once tumor was established, mice were randomly divided to 4 groups (n = 8) and treated with either free anti-EpCAM antibody or different doses of anti-EpCAM-amanitin conjugates (ADC). d Quantification of RBX1 knockdown efficiency, cell proliferation (Ki-67 staining) and apoptosis (cleaved caspase-3 staining) in the xenografted tumor tissues described above. Data are analyze by unpaired two-tailed t-test and are presented as the mean ± SD. **, p < 0.01; ***, p < 0.001